Atrial fibrillation as an acute severity amplifier during cancer hospitalizations: A National Inpatient Sample analysis, 2018–2022.
Abstract
e23098 Background: Atrial fibrillation (AF) is highly prevalent among patients with cancer and is frequently treated as a chronic comorbidity during hospitalization. Whether the presence of AF during cancer hospitalizations independently amplifies acute inpatient severity, critical care utilization, and mortality at a national level remains incompletely defined. Methods: A serial cross-sectional analysis was performed using adult hospitalizations with a principal diagnosis of malignancy in the 2018–2022 Healthcare Cost and Utilization Project National Inpatient Sample. AF/atrial flutter was identified using any-diagnosis ICD-10-CM code I48*. Outcomes included All Patient Refined Diagnosis Related Group (APR-DRG) severity of illness, extreme severity (APR-DRG level 4), in-hospital mortality, shock (R57*), mechanical ventilation, length of stay (LOS), and hospitalization cost. National estimates accounted for survey stratification, clustering, and discharge-level weighting. Survey-weighted multivariable regression adjusted for demographics, payer, ZIP-code income quartile, admission characteristics, cancer type, hospital characteristics, and year. Results: Among 961,848 unweighted cancer hospitalizations, representing 4,809,239 admissions nationally, AF was present in 11.9%. Hospitalizations with AF demonstrated substantially higher acuity compared with those without AF. Mean APR-DRG severity was higher (2.99 vs 2.50), and extreme severity occurred more frequently (5.19% vs 3.22%). In-hospital mortality was nearly doubled among AF-associated admissions (7.75% vs 3.93%). AF was also associated with higher rates of shock (2.83% vs 1.19%) and mechanical ventilation (4.97% vs 2.26%), longer LOS (8.23 vs 6.44 days), and greater hospitalization costs ($26,265 vs $22,365). After multivariable adjustment, AF remained independently associated with increased inpatient severity (APR-DRG severity β 0.38, 95% CI 0.36–0.39), extreme severity (odds ratio [OR] 1.79, 95% CI 1.72–1.86), in-hospital mortality (OR 1.75, 95% CI 1.70–1.80), shock (OR 2.34, 95% CI 2.23–2.44), and mechanical ventilation (OR 2.36, 95% CI 2.28–2.44). Conclusions: Atrial fibrillation occurring during cancer-related hospitalizations functions as an acute inpatient severity amplifier. The presence of AF as a comorbidity was independently associated with higher illness severity, ICU-level care, and mortality. These findings support reframing and prioritizing AF as a clinically actionable marker of inpatient decompensation rather than a chronic comorbidity, with implications for early risk stratification and escalation strategies in hospitalized oncology populations.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (6)
Christopher Aboujaoude
HCA Sunrise Health GME Consortium - MountainView Hospital, Las Vegas, NV
Sharnvir Chattha
HCA Sunrise Health GME Consortium - MountainView Hospital, Las Vegas, NV
Boone Singtong
HCA Sunrise Health GME Consortium - MountainView Hospital, Las Vegas, NV
Daniel Thomas Jones
HCA Sunrise Health GME Consortium - MountainView Hospital, Las Vegas, NV
Pinak Shah
From Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, NJ (P.G.); Columbia University Medical Center/New York Presbyterian Hospital (A.S., R.T.H., M.B.L.), the Cardiovascular Research Foundation (D.J.C., R.T.H., B.R., M.B.L.), and Weill Cornell Medicine (B.R.), New York, and St. Francis Hospital and Heart Center, Roslyn (D.J.C.) — all in New York; University of Colorado Health, Medical Center of the Rockies, Loveland (J.B.O.); Laval University, Quebec, QC (P.P.), St. Paul’s Hospital, University of British Columbia, Vancouver (P.B., J.L.), and McMaster University, Hamilton, ON (T.S.) — all in Canada; Vanderbilt University Medical Center, Nashville (B.R.L., K.G.); Emory University, Atlanta (V.B.); the Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, Stanford (W.F.F.), VA Palo Alto Health Care System, Palo Alto (W.F.F.), California Pacific Medical Center, San Francisco (D.V.D.), Cedars–Sinai Medical Center, Los Angeles (R.R.M.), and Edwards ...
Kyaw Zin Thein
3Comprehensive Cancer Centers of Nevada, Division of Hematology and Medical Oncology, Las Vegas, United States